FDA warning: Fluconazole may cause birth defects

Article

Long-term use of high doses of fluconazole during pregnancy may be associated with birth defects, according to the FDA.

Long-term use of high doses of fluconazole (Diflucan) during pregnancy may be associated with birth defects, according to the FDA.

The agency issued a warning stating that chronic use of fluconazole in doses of 400 mg to 800 mg per day during the first trimester of pregnancy may be associated with a "rare and distinct set of birth defects." As a result, FDA changed the category of the drug in that dosage from C to D, meaning that positive evidence exists regarding human fetal risk based on human data, but that potential benefits of using the drug in pregnant women with serious or life-threatening conditions may outweigh the risks. The agency noted that a single low dose, used frequently to treat vaginal candidiasis, remains category C.

Birth defects noted include abnormal head, skull, and facial defects; cleft palate and/or lip; bowing of the thigh bones; thin ribs; long bones; muscle weakness; joint deformities; and congenital heart disease at birth. The information came from 5 case studies. Four of the 5 women took fluconazole to treat meningitis; the remaining woman was HIV-positive and used chronic, high doses of fluconazole to treat a vaginal yeast infection.

FDA also encourages healthcare professionals and patients to report adverse events or side effects related to the use of fluconazole to the FDA's MedWatch Safety Information and Adverse Event Reporting Program by completing and submitting the report online at http://www.fda.gov/MedWatch/report.htm; by downloading the form from http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm; or by calling 1-800-332-1088 to request a reporting form. Completed forms should be returned to the address on the preaddressed form or submitted by fax to 1-800-FDA-0178.

Diflucan (fluconazole): Drug Safety Communication-Long-term, high-dose use during pregnancy may be associated with birth defects [news release]. US Food and Drug Administration; August 3, 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm266468.htm. Accessed August 7, 2011.

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Deciding the best treatment for uterine fibroids | Image Credit: jeffersonhealth.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
Related Content
© 2024 MJH Life Sciences

All rights reserved.